Related references
Note: Only part of the references are listed.Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study
Federica Martella et al.
ANNALS OF HEMATOLOGY (2022)
Prevalence and impact of diabetes in hospitalized COVID-19 patients: A systematic review and meta-analysis
Sian A. Bradley et al.
JOURNAL OF DIABETES (2022)
Incidence and Risk Factors for Venous Thromboembolism in Female Patients Undergoing Breast Surgery
Ambrogio P. Londero et al.
CANCERS (2022)
Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release
Antonio Gidaro et al.
JOURNAL OF CLINICAL MEDICINE (2022)
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019
Khanh Bao Tran et al.
LANCET (2022)
PhaseIIstudy evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE1)
Eric Assenat et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Effect of prehospital workflow optimization on treatment delays and clinical outcomes in acute ischemic stroke: A systematic review and meta-analysis
Seemub Zaman Chowdhury et al.
ACADEMIC EMERGENCY MEDICINE (2021)
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
Antoinette R. Tan et al.
LANCET ONCOLOGY (2021)
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Juan W Valle et al.
LANCET ONCOLOGY (2021)
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Fred Saad et al.
LANCET ONCOLOGY (2021)
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Gary H. Lyman et al.
BLOOD ADVANCES (2021)
Venous thromboembolism in cancer patients: a population-based cohort study
F. Mulder et al.
BLOOD (2021)
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial
E. Assenat et al.
ESMO OPEN (2021)
Diagnostic and prognostic utility of computed tomography perfusion imaging in posterior circulation acute ischemic stroke: A systematic review and meta-analysis
Anubhav Katyal et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES) : a randomised, double-blind, placebo-controlled, phase 2 trial
Carmine Pinto et al.
LANCET ONCOLOGY (2021)
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study
Xavier Deschenes-Simard et al.
THROMBOSIS RESEARCH (2021)
The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation
Kristoffer Ottosson et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2020)
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08
Martin Fehr et al.
BMC CANCER (2020)
Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer
Julia Rose Salinaro et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study
Xiaoli He et al.
BMC CANCER (2020)
Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study
Stavros K. Kakkos et al.
INTERNATIONAL ANGIOLOGY (2020)
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini et al.
LANCET ONCOLOGY (2020)
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis
Stefan Hohaus et al.
CANCERS (2020)
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment
Jung-Min Lee et al.
GYNECOLOGIC ONCOLOGY (2020)
Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial
Astrid E. Slagter et al.
CANCER MEDICINE (2020)
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles et al.
LANCET ONCOLOGY (2020)
PhaseIIstudy of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer
Motoko Tachihara et al.
THORACIC CANCER (2020)
Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management
Marwa S. Hamza et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2020)
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET ONCOLOGY (2019)
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
A. A. Khorana et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
Andrea DeCensi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Zafar Usmani et al.
LANCET HAEMATOLOGY (2019)
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Risk Factors Associated With Venous Thromboembolism
John Gregson et al.
JAMA CARDIOLOGY (2019)
Preventing Venous Thromboembolism in Patients with Cancer
Lorenzo D'Ambrosio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill
Benjamin Brenner et al.
THROMBOSIS JOURNAL (2019)
Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas
Melissa Frizziero et al.
NEUROENDOCRINOLOGY (2019)
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
Ashley Ghiaseddin et al.
ONCOLOGIST (2018)
A randomized phase II trial of interleukin-2 and interferon- plus bevacizumab versus interleukin-2 and interferon- in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1
Frede Donskov et al.
ACTA ONCOLOGICA (2018)
Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study
Elvira Buxo et al.
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY (2018)
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
Mary Lou Affronti et al.
ONCOLOGIST (2018)
Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
German Reyes-Botero et al.
ONCOLOGIST (2018)
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim et al.
LANCET ONCOLOGY (2018)
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2018)
Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment
Norbaini Binti Abdol Razak et al.
CANCERS (2018)
Venous thromboembolism and cancer risk
Per Sanden et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2017)
Adherence to thromboprophylaxis guidelines in elderly patients with hospital acquired venous thromboembolism: a case control study
Jason Suh et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2017)
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival
Jorge D. Ramos et al.
CANCER MEDICINE (2017)
Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study
Sara Lindstrom et al.
HUMAN GENETICS (2017)
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study CALGB 30607 (Alliance)
Maria Q. Baggstrom et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari et al.
LANCET (2017)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio et al.
LANCET ONCOLOGY (2017)
Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer
Devendra Manik Chavan et al.
MEDICINE (2017)
Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis
Umair T. Khan et al.
BMC CANCER (2017)
Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study
Hiromitsu Kitayama et al.
BMC CANCER (2017)
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma
Jia Li et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer
Fred R. Hirsch et al.
CLINICAL LUNG CANCER (2017)
Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience
Naoko Ishida et al.
BREAST CANCER (2016)
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
K. Yamazaki et al.
ANNALS OF ONCOLOGY (2016)
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study
G. Folprecht et al.
ANNALS OF ONCOLOGY (2016)
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Gaspar Reynes et al.
ANTI-CANCER DRUGS (2016)
Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)
A. Matikas et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Vascular Toxicities of Cancer Therapies The Old and the New - An Evolving Avenue
Joerg Herrmann et al.
CIRCULATION (2016)
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay
Primo N. Lara et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Deep vein thrombosis and pulmonary embolism
Marcello Di Nisio et al.
LANCET (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss et al.
LANCET ONCOLOGY (2016)
Ischemic Stroke and Risk of Venous Thromboembolism in the General Population: The Tromso Study
Ludvig B. Rinde et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
J. Guigay et al.
ANNALS OF ONCOLOGY (2015)
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer
Rory J. Makielski et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503)
Koji Matsumoto et al.
GYNECOLOGIC ONCOLOGY (2015)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer
Shinnosuke Ikemura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
Madeleine Duvic et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
Gottfried E. Konecny et al.
LANCET ONCOLOGY (2015)
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
Harry D. Bear et al.
LANCET ONCOLOGY (2015)
Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment
Long Bai et al.
MEDICAL ONCOLOGY (2015)
A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer
Wei Hu et al.
MEDICAL ONCOLOGY (2015)
Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer - a clinical prospective study of outcome and prognostic factors
Anders Christian Larsen et al.
THROMBOSIS RESEARCH (2015)
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
Robert Chen et al.
HAEMATOLOGICA (2015)
A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)
Hiroyuki Uetake et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in suboptimal patients with advanced gastric cancer (AGC). TTD 08-02
F. Rivera et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group
Esther Tahover et al.
TARGETED ONCOLOGY (2015)
Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day
Chris Gardiner et al.
JOURNAL OF EXTRACELLULAR VESICLES (2015)
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
Lubomir Slavicek et al.
BMC GASTROENTEROLOGY (2014)
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
J. Feliu et al.
BRITISH JOURNAL OF CANCER (2014)
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study
Gini F. Fleming et al.
GYNECOLOGIC ONCOLOGY (2014)
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group
Kristen K. Ciombor et al.
INVESTIGATIONAL NEW DRUGS (2014)
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Sven de Vos et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer
Bohdan Kadlec et al.
SCIENTIFIC WORLD JOURNAL (2014)
Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer
Ulka N. Vaishampayan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
A. F. C. Okines et al.
ANNALS OF ONCOLOGY (2013)
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
K. Tryfonidis et al.
BREAST (2013)
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
M. Peeters et al.
BRITISH JOURNAL OF CANCER (2013)
A Randomized Phase 2 Study of Temozolomide and Bevacizumab or nab-Paclitaxel, Carboplatin, and Bevacizumab in Patients With Unresectable Stage IV Melanoma A North Central Cancer Treatment Group Study, N0775
Lisa A. Kottschade et al.
CANCER (2013)
Venous Thromboembolism and Cancer
Gregory Piazza
CIRCULATION (2013)
Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non-Small-Cell Lung Cancer
Steven F. Powell et al.
CLINICAL LUNG CANCER (2013)
Incidence of venous thromboembolism in patients with cancer - A cohort study using linked United Kingdom databases
Alex J. Walker et al.
EUROPEAN JOURNAL OF CANCER (2013)
Phase II trial of combination bevacizumab and temsirolimus in the treatment of A recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
Edwin A. Alvarez et al.
GYNECOLOGIC ONCOLOGY (2013)
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
Yong Sang Hong et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
Arjun V. Balar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806)
Brian M. Alexander et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network
C. Seidel et al.
JOURNAL OF NEUROLOGY (2013)
An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan
Kuan-Der Lee et al.
ONCOLOGY (2013)
Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70 years)
Umberto Basso et al.
JOURNAL OF GERIATRIC ONCOLOGY (2013)
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
G. Sonpavde et al.
ANNALS OF ONCOLOGY (2012)
Phase II open-label study of sunitinib in patients with advanced breast cancer
Denise A. Yardley et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer
Andrew S. Epstein et al.
CANCER (2012)
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer
Robert A. Wolff et al.
CANCER (2012)
Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer
James P. Stevenson et al.
CANCER (2012)
Venous thromboembolism (VTE) in patients with advanced gastric cancer: An Asian experience
Myoung Joo Kang et al.
EUROPEAN JOURNAL OF CANCER (2012)
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
I. Lang et al.
EUROPEAN JOURNAL OF CANCER (2012)
Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer
Henrik Toft Sorensen et al.
EUROPEAN JOURNAL OF CANCER (2012)
Crosstalk between cancer and haemostasis Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor
F. Langer et al.
HAMOSTASEOLOGIE (2012)
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies
Francois Ghiringhelli et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma†
Motoo Nagane et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer
Ramazan Yildiz et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients
J. Thaler et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Pulmonary embolism and deep vein thrombosis
Samuel Z. Goldhaber et al.
LANCET (2012)
Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group
Giannis Mountzios et al.
LUNG CANCER (2012)
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma
Jonathan E. Dowell et al.
LUNG CANCER (2012)
A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer
Bjorn H. Gronberg et al.
LUNG CANCER (2012)
Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium
Nicholas P. Campbell et al.
LUNG CANCER (2012)
Prospective Phase II Study of Neoadjuvant Therapy with Cisplatin, 5-Fluorouracil, and Bevacizumab for Locally Advanced Resectable Esophageal Cancer
Efraim Idelevich et al.
ONKOLOGIE (2012)
High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis
Russell A. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Francesca Gay et al.
BLOOD (2010)
Epidemiology and pathophysiology of cancer-associated thrombosis
S. Noble et al.
BRITISH JOURNAL OF CANCER (2010)
Risk Factors for Venous Thromboembolism
Samuel Z. Goldhaber
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Common risk factors for both arterial and venous thrombosis
Gordon D. O. Lowe
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Plasminogen activator inhibitor-1 in vascular thrombosis
Randal J. Westrick et al.
CURRENT DRUG TARGETS (2007)
Incidence of venous thromboembolism in patients hospitalized with cancer
PD Stein et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
AA Khorana et al.
CANCER (2005)
Incidence of diagnosed deep vein thrombosis in the general population: Systematic review
FJI Fowkes et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2003)
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism - A population-based study
JA Heit et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials
M Oremus et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2001)
Share Paper
